Validation of Academic Research Consortium for High Bleeding Risk Definition in East-Asian Patients.

ABSTRACT:

Background

Clinical applicability of the Academic Research Consortium High Bleeding Risk (ARC-HBR) criteria in East-Asian patients receiving potent antiplatelet therapy for acute coronary syndromes (ACS) is still undetermined.

Objectives

The purpose of this study was to validate the ARC definition for HBR in East-Asian patients with ACS for invasive management.

Methods

We analyzed data from the TICAKOREA (Ticagrelor Versus Clopidogrel in Asian/Korean Patients With ACS Intended for Invasive Management) trial and randomly assigned 800 Korean ACS subjects to receive, in a 1:1 ratio, ticagrelor or clopidogrel. Patients were considered HBR if they met at least 1 major or 2 minor ARC-HBR criteria. The primary bleeding endpoint was Bleeding Academic Research Consortium 3 or

SUBMITTER: Lee J 

PROVIDER: S-EPMC10261889 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature